Lir生命科学完成动物研究测试,为肥胖症药物测试无针补丁,目的是改善获得治疗和坚持治疗的机会。 Lir Life Sciences finishes animal study testing needle-free patches for obesity drugs, aiming to improve treatment access and adherence.

Lir Life Sciences 已完成设计一项比较动物研究，以测试其经皮递送平台，利用细胞穿透肽实现无针给药GLP/GIP类肥胖治疗。 Lir Life Sciences has completed designing a comparative animal study to test its transdermal delivery platform, using cell-penetrating peptides to enable needle-free administration of GLP/GIP-based obesity therapies. 这项研究与科学伙伴一起进行,将评估在口服挑战后,变性配方如何有效地控制血糖,并将其与标准的亚皮注射进行比较。 The study, conducted with scientific partners, will evaluate how effectively transdermal formulations control blood glucose after an oral challenge, comparing them to standard subcutaneous injections. 它旨在确定哪些GLP/GIP疗法在补丁技术方面表现最佳,指导今后的开发、配方优化和调查性新药物(IND)规划。 It aims to identify which GLP/GIP therapies perform best with the patch technology, guiding future development, formulation optimization, and Investigational New Drug (IND) planning. 该公司的目标是为注射治疗创造负担得起的、对病人友好的替代办法,改善对新陈代谢疾病疗法的遵守和获得。 The company’s goal is to create affordable, patient-friendly alternatives to injectable treatments, improving adherence and access to metabolic disease therapies. 预计结果将为临床战略提供信息,并支持通过创新的交付方法扩大治疗选择的更广泛努力。 Results are expected to inform clinical strategy and support broader efforts to expand treatment options through innovative delivery methods.